Further to the announcement on July 28, 2025, Avacta Group plc (AIM: AVCT) a life sciences company developing innovative, targeted oncology drugs, today announced that all closing conditions to the sale of the entire issued share capital of Coris Bioconcept SRL to 3B BlackBio Dx Ltd have been satisfied and the completion of the sale took place on Friday August 29, 2025.